EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma

Hiroki Ishihara, Hironori Fukuda, Yukihiro Mizoguchi, Makiko Yamashita, Kazunori Aoki, Ryo Ishiyama, Takashi Ikeda, Yuki Nemoto, Hiroaki Shimmura, Yasunobu Hashimoto, Kazuhiko Yoshida, Toshihito Hirai und 5 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03876-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Hiroki Ishihara und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Lymphocytes, Tumor-Infiltrating, Immunotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sex differences in the outcomes of advanced renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICIs) and the profiles of tumor-infiltrating immune cells (TIICs) remain unclear. We retrospectively evaluated data from 563 patients with RCC receiving systemic therapy, including first-line dual ICI combinations (i.e., immunotherapy [IO]-IO), combinations of ICIs with tyrosine kinase inhibitors (TKIs) (i.e., IO-TKI), TKI monotherapy, and subsequent nivolumab monotherapy. Survival and tumor response were compared between the sexes in each treatment group, and TIIC profiles were compared using 116 RCC tumor samples analyzed by flow cytometry. Progression-free survival (PFS) was shorter in female than in male patients in the IO-IO ( p = 0.0227) and nivolumab monotherapy ( p = 0.0478) groups. Furthermore, sex remained an independent factor for shorter PFS after adjusting for covariates in the IO-IO ( p = 0.0340) and nivolumab monotherapy ( p = 0.0322) groups. In contrast, PFS was not significantly different between sexes in the IO-TKI or TKI monotherapy groups ( p > 0.05). Overall survival and objective response rates were not significantly different between the sexes in any of the treatment groups ( p > 0.05). Some TIIC populations, including that of CD8 + T cells ( p = 0.0096), decreased to a greater extent in female than in male patients in the advanced-stage population. In conclusion, the effectiveness of ICIs on PFS was lower in female patients than in male patients, potentially because of the different profiles of the immune microenvironment, particularly the decreased number of CD8 + T cells in females.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsLymphocytes, Tumor-InfiltratingImmunotherapyHumansFemaleMaleMiddle AgedAgedRetrospective StudiesSex FactorsAdultImmune Checkpoint InhibitorsAged, 80 and overTumor MicroenvironmentTreatment Outcome

Stichwörter der Autor:innen

Kidney cancermetastatic renal cell carcinomatumor infiltrating immune celltumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
  • Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan. fukuda.hironori@twmu.ac.jp.
  • Department of Immune Medicine, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan.
  • Division of Cancer Immunotherapy Development, Center for Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-Ku, Tokyo, Japan.
  • Department of Urology, Saiseikai Kazo Hospital, Kamitakayanagi, Kazo, Saitama, 1680, Japan.
  • Department of Urology, Jyoban Hospital, Uenodai 57, Joban Kamiyunagayamachi, Iwaki, Fukushima, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Ishihara, H., Fukuda, H., Mizoguchi, Y., Yamashita, M., Aoki, K., Ishiyama, R., Ikeda, T., Nemoto, Y., Shimmura, H., Hashimoto, Y., Yoshida, K., Hirai, T., Iizuka, J., Tokita, D., Kondo, T., Nagashima, Y., & Takagi, T. (2025). Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03876-2

Vancouver

Ishihara H, Fukuda H, Mizoguchi Y, Yamashita M, Aoki K, Ishiyama R, et al. Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03876-2

BibTeX
@article{Ishihara2025,
  author = {Ishihara, Hiroki and Fukuda, Hironori and Mizoguchi, Yukihiro and Yamashita, Makiko and Aoki, Kazunori and Ishiyama, Ryo and Ikeda, Takashi and Nemoto, Yuki and Shimmura, Hiroaki and Hashimoto, Yasunobu and Yoshida, Kazuhiko and Hirai, Toshihito and Iizuka, Junpei and Tokita, Daisuke and Kondo, Tsunenori and Nagashima, Yoji and Takagi, Toshio},
  title = {Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03876-2}
}
Kostenlos starten →